Dynavax Technologies Corp (DVAX)

10.00
0.35 3.38
NASDAQ : Health Care
Prev Close 10.35
Open 10.40
Day Low/High 9.90 / 10.53
52 Wk Low/High 12.84 / 32.49
Volume 2.31M
Avg Volume 1.42M
Exchange NASDAQ
Shares Outstanding 48.79M
Market Cap 485.50M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and...

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Commit To Purchase Dynavax Technologies Corp At $6, Earn 78.3% Annualized Using Options

Investors eyeing a purchase of Dynavax Technologies Corp stock, but cautious about paying the going market price of $6.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $6 strike, which has a bid at the time of this writing of $1.75.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

2 Questions From the Biotech Mailbag

2 Questions From the Biotech Mailbag

A look at how lawsuits and FDA changes could impact the industry.

Short Interest Decreases By 14.2% For DVAX

The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 1,200,260 share decrease in total short interest for Dynavax Technologies Corp , to 7,245,226, a decrease of 14.21% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - DVAX

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - DVAX

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Dynavax Technologies Corporation (NASDAQ: DVAX) between March...

DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017

DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (NASDAQ:DVAX)...

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Dynavax Technologies Corporation To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Dynavax Technologies Corporation To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Dynavax Technologies Corporation (NASDAQ:DVAX) between March 10,...

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017

DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (NASDAQ:...

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Dynavax Technologies Corporation Investors And Encourages Investors To Contact The Firm

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Dynavax Technologies Corporation Investors And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX) securities...

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech

5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech

These stocks are within range of triggering breakout trades. Here's how to trade them from here.

Oversold Conditions For Dynavax Technologies (DVAX)

Oversold Conditions For Dynavax Technologies (DVAX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against Dynavax Technologies Corporation And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against Dynavax Technologies Corporation And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Dynavax Technologies Corporation ("Dynavax" or the "Company") (Nasdaq: DVAX).